SCG-101 is under clinical development by SCG Cell Therapy and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase II drugs for Bile Duct Cancer (Cholangiocarcinoma) have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SCG-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SCG-101 overview

SCG-101 is under development for the treatment of hepatocellular carcinoma, bile duct cancer (cholangiocarcinoma) and chronic hepatitis B. The therapeutic candidate comprises of autologous T cells which are genetically modified to express T cell receptors (TCR) targeting epitopes of hepatitis B surface antigen (HBsAg). It is administered through intravenous route. It is being developed based on GianT technology.

SCG Cell Therapy overview

SCG Cell Therapy (SCG) is a biotechnology company that discovers and develop novel immunotherapies to treat chronic infections and pathogen-associated solid tumors. The company is investigating its pipeline products including SCG101, SCG002 and SCG102, a t-cell therapies targeting hepatocellular carcinoma (HCC) and liver cancer; SCG142, an HPV TCR-T therapy for the treatment of cervical cancer and SCG201, SCG211, a bispecific antibody for hepatitis B infection. It is also evaluating SCG321, a therapeutic vaccine against helicobacter pylori infection. SCG works in collaboration with Helmholtz Zentrum Munchen, The Technical University of Munich (TUM) and German Cancer Research Center (DKFZ). The company has operations in China and Germany. SCG Cell Therapy is headquartered in Singapore City, Singapore.

For a complete picture of SCG-101’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.